Developing Saliva-based Lateral Flow Immunoassays

Thursday, July 28
11 – 11:20 a.m.
Exhibit Hall Theater 1
Presentation by Fortis Life Sciences


With the revolution of lateral flow assay use in point-of-care and over-the-counter testing resulting from COVID-19, saliva has become an attractive sample matrix. To continue to grow lateral flow assay use in these sectors, there is a need for simple and non-invasive testing that saliva as a matrix can provide. However, it is not without its challenges. Saliva is prone to matrix effects, varies greatly from patient to patient, and may have lower analyte concentrations than other sample types. Additionally, saliva can be a very difficult matrix to work in because of complexities surrounding the collection, filtration, and dispensing of sample onto a test. In this session, we will discuss how proper planning and the selection of reagents can address these unique challenges to produce a successful saliva-based lateral flow assay.


After attending this session, participants will be able to:

  • Understand the unique challenges of saliva relative to other sample matrices
  • Learn how reporter probe selection can help achieve high sensitivity even in difficult matrices
  • Learn approaches to successful saliva-based lateral flow assay design that enable scaled manufacturing


Andre Alfaro
Senior Director of Assay Development
Fortis Life Sciences

Sowmya Kedarnath
Senior Marketing Programs Manager
Fortis Life Sciences